===Crinetics Pharmaceuticals (CRNX) to be acquired by Vertex Pharmaceuticals (VRTX)

 

Vertex to acquire Crinetics for $85 per share in cash in ~$10 billion deal, expanding into rare endocrine diseases

• Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for $85.00 per share in an all-cash deal valued at approximately $10.0 billion. 
• Expected to close in the third quarter of 2026.
• The acquisition follows Crinetics' 2018 public debut and provides Crinetics (NASDAQ: CRNX) with significant premium valuations, integrating its endocrine pipeline into Vertex.